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Background: Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term
biochemical changes leading to spontaneous seizures. This study tested the effect of eslicarbazepine acetate (ESL),
a novel antiepileptic drug, on latrunculin A-induced acute and chronic seizures, and changes in brain amino acid
extracellular levels. Hippocampi of Swiss mice were continuously perfused with a latrunculin A solution (4 μM, 1 μl/min,
7 h/day) with continuous EEG and videotape recording for 3 consecutive days. Microdialysate samples were analyzed
by HPLC and fluorescence detection of taurine, glycine, aspartate, glutamate and GABA. Thereafter, mice were
continuously video monitored for two months to identify chronic spontaneous seizures or behavioral changes.
Control EEG recordings (8 h) were performed in all animals at least once a week for a minimum of one month.
Results: Oral administration of ESL (100 mg/kg), previous to latrunculin A microperfusion, completely prevented
acute latrunculin A-induced seizures as well as chronic seizures and all EEG chronic signs of paroxysmal activity.
Hippocampal extracellular levels of taurine, glycine and aspartate were significantly increased during latrunculin A
microperfusion, while GABA and glutamate levels remained unchanged. ESL reversed the increases in extracellular
taurine, glycine and aspartate concentrations to basal levels and significantly reduced glutamate levels. Plasma
and brain bioanalysis showed that ESL was completely metabolized within 1 h after administration to mainly
eslicarbazepine, its major active metabolite.
Conclusion: ESL treatment prevented acute latrunculin A-induced seizures as well as chronic seizures and all EEG
chronic signs of paroxysmal activity, supporting a possible anti-epileptogenic effect of ESL in mice.
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Eslicarbazepine acetate (ESL) is a once-daily anticonvul-
sant approved in 2009 by the European Medicines
Agency (EMA) and in 2013 by the Food and Drug Ad-
ministration (FDA) as adjunctive therapy in adults with
partial-onset seizures (POS). The ESL epilepsy clinical* Correspondence: psoares.silva@bial.com
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unless otherwise stated.program included an initial proof of concept phase II
study [1] and four subsequent phase III studies in patients
refractory to conventional antiepileptic drug (AED)
therapy [2-5]. Long-term safety and maintenance of
therapeutic effect was demonstrated in one-year open-
label extensions of these studies [6-8].
Following oral administration, ESL undergoes exten-
sive first pass hydrolysis to its major active metabolite
eslicarbazepine (also known as (S)-licarbazepine) [9-13],
which represents approximately 95% of circulating active
moieties and is believed to be responsible for its antiseizurentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Antiseizure effects of ESL and exposure to
eslicarbazepine. A) Anticonvulsant dose-response curves for ESL
against tonic convulsions in the mouse MES test seizure model.
Symbols represent mean values of 12-15 animals per group. B)
Plasma concentrations of eslicarbazepine and oxcarbazepine after
oral administration ESL. Symbols represent mean values of 4 animals
per group; vertical lines indicate SEM.
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availability due to enhancement of slow inactivation of
voltage-gated sodium channels and blockade type T cal-
cium channels [17-19].
Latrunculin A is an actin depolymerization agent [20]
that has been widely used to study the role of F-actin in
anchoring NMDA receptors to synaptic sites [21,22].
Latrunculin A treatment promotes neurotransmitter re-
lease in hippocampal synapses [23] and induces multiple
action potential firing and increases action potential
duration [24]. Latrunculin A hippocampal microperfusion
in freely moving rats induces acute epileptic seizures,
followed by the occurrence of chronic sporadic spontan-
eous seizures, in association with changes in extracellular
concentrations of excitatory and inhibitory amino acids
[25,26]. In the rat, ESL was found to prevent acute seizures
induced by latrunculin A hippocampal microperfusion and
reduce the increases in glutamate and aspartate induced by
latrunculin A [25]. However, rats, in contrast to mice and
humans, extensively convert ESL to oxcarbazepine [27].
The aim of the present study was to evaluate the ef-
fects of ESL on the development of latrunculin A hippo-
campal perfusion-induced acute and chronic seizure
model in the mouse and to further examine the effects
upon hippocampal extracellular levels of taurine, glycine,
aspartate, GABA and glutamate, as changes in the extra-
cellular levels of these amino acids play determinant ef-
fects in the neuropathophysiology of epileptic seizures
[28-39]. Mice were used for the experiments as the me-
tabolism of ESL in this species reflects the situation ob-
served in humans [27,40,41].
Results
MES test
Male NMRI mice (n = 12-15 per group) were administered
MES (50 mA, rectangular current: 0.6 ms pulse width,
0.4 s duration, 50 Hz) via corneal electrodes connected to
a constant current shock generator (Ugo Basile 7801) and
the number of tonic convulsions recorded. ESL (2.5 to
150 mg/kg) decreased in dose dependent manner MES-
induced seizures (Figure 1A) with an ED50 values of 23.0 ?
1.9 mg/kg. Following oral administration of ESL, the major
metabolite in plasma obtained from a statelite group of
mice was eslicarbazepine, followed by relatively low
amounts of OXC (Figure 1B); no trace amounts of ESL
and R-licarbazepine were detected. The ESL dose of
100 mg/kg administered 60 min before the test resulted in
90% protection against MES-induced seizures. The con-
centration of eslicarbazepine in plasma associated with the
90% protection against MES-induced seizures was 126.6 ?
16.4 nmol/ml. Because this dose of ESL was found not to
affect the behavioural performance in the rotarod test (data
not shown), subsquent experiments (see below) were per-
formed with the 100 mg/kg ESL dose.EEG and behavioral observations
No seizures were observed during the first and second day
of latrunculin A hippocampal microperfusion. However, all
animals (n = 8 per group) studied showed a variable num-
ber of seizures (4.6 ? 2.8) on the third day of latrunculin A
hippocampal microperfusion. ESL (100 mg/kg), adminis-
tered 5? 10 min before starting latrunculin A hippo-
campal perfusion, completely prevented latrunculin A
induced seizures in all mice studied.
During the first week after latrunculin A treatment no
behavioral signs or paroxysmal EEG activity was ob-
served, though sporadic periods of slow waves were
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signals of paroxysmal activity (electrographic seizures,
focal and bilateral spike and wave discharges and long pe-
riods of slow wave activity) were recorded in all animals
studied. Three different types of paroxysmal activity were
observed in the same animal (Figure 2): 1) short bilateral
electrographic seizure appearing sporadically during the
second week after latrunculin A hippocampal microperfu-
sion (typically 2 or 3 events during the 8 hours of control
recording, but without accompaning convulsions or
absence-like behavior); 2) focal spike discharges observed
the third week after latrunculin A treatment, not related
to observable behavioral signs; 3) slow waves/polyspikes
observed during the third and fourth day of control (con-
sisting of more than 30% of the 8-hours EEG recording,
and occurring more frequently during sleep).
EEG epileptiform activity during the four weeks fol-
lowing latrunculin A hippocampal microperfusion was
summarized weekly according to time spent (duration)
in bilateral spike and wave discharges, focal discharges
or slow wave activity (Figure 3). Among the mice studied,
electrographic seizures and discharges occurred far more
frequently than corresponding behavioral seizures could
be detected. One tonic-clonic seizure was observed in
two of the animals studied during behavioral observation,
but no EEG records were obtained. Bilateral spike and
wave discharges, focal discharges or slow wave activity
resulting from latrunculin A hippocampal microperfusionFigure 2 Chronic effect of latrunculin A hippocampal microperfusion
(FOR, fronto-occipital right; FOL, fronto-occipital left). B) Contralateral spikes
C) Slow wave activity recorded during the third week after latrunculin A hiwere significantly lower in ESL-treated mice than in
vehicle-treated mice (P < 0.001, using the by two-way
ANOVA followed by Holm-Sidak? s multiple comparisons
test; Figure 3).
In the animals treated with ESL, no paroxysmal EEG
activity was observed during wakefulness and sleep in the
month following latrunculin A microperfusion (Figure 4).
No observable seizures or behavioural abnormalities were
observed during the continuous video recordings of ESL-
treated animals.
The inter-rater variability in the assessment of video-
taped seizures and behavioral changes was approxi-
mately 2%.
Extracellular amino acid levels
Hippocampal extracellular aspartate (Asp), glutamate
(Glu), glycine (Gly), GABA and taurine (Tau) were ob-
tained with a 4-mm microdialysis membrane at a flow
rate of 2 μl/min and were corrected for probe recovery.
The recovery of Asp, Glu, Gly, GABA and Tau across
the dialysis membrane was determined by perfusing
modified Ringer solution at a rate of 2 μl/min through
standard amino acid solutions ranging from 0.5 to
100 mM. Samples were collected every 15 min and de-
termined as described. Relative probe recovery values
(% mean ? SEM) were 23.3 ? 2.3 for Asp, 24.0 ? 3.0 for
Glu, 33.2 ? 3.9 for Gly, 21.1 ? 2.3 for GABA and 14.6 ?
5.7 for Tau.of in freely moving mice. A) EEG recording of a spontaneous seizure
recorded two weeks after latrunculin A hippocampal microperfusion.
ppocampal microperfusion.
Figure 3 Average duration of the weekly EEG epileptiform
activity (bilateral spike and wave discharges, focal discharges and
slow wave activity) recorded during the four weeks following
latrunculin A hippocampal microperfusion in vehicle-treated and
ESL-treated mice. Columns represent mean values of 8 animals
per group; vertical lines indicate SEM. Significantly different from
corresponding values in latrunculin A-treated mice using the
two-way ANOVA followed by Holm-Sidak ? s multiple comparisons
test (*P < 0.001).
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0.15 ? 0.02 μmol/l for Asp, 3.53 ? 0.42 μmol/l for Glu,
2.66 ? 0.27 μmol/l for Gly, 0.04 ? 0.01 μmol/l for GABA
and 3.54 ? 0.44 μmol/l for Tau. As shown in Figure 5,
latrunculin A hippocampal microperfusion induced sig-
nificant (P < 0.001) increases in extracellular concentra-
tions of Gly and Tau on days 1, 2 and 3 of latrunculin Ahippocampal microperfusion, as well as a significant
(P < 0.05) decrease in GABA levels, when were com-
pared to control animals. Asp concentrations were sig-
nificnatly (P < 0.01) increased during day 2 of perfusion.
Glu levels remained unchanged during the two first days
of perfusion, but decreased during the third day (P =
0.0553). The treatment with ESL prevented the latruncu-
lin A-induced increase in Gly, Asp and Tau microdialy-
sate concentrations (Figure 5). Though perfusion with
latrunculin A did not affect extracellular concentrations
of Glu during the first 2 days of treatment, ESL never-
theless markedly decreased the concentrations of Glu in
the microdialysate of latrunculin A perfused mice during
days 1 (P = 0.023) and 2 (P = 0.024). On the other hand,
the marked decrease in GABA concentrations in the
microdialysate of latrunculin A perfused mice was not
affected by ESL administration.
Taking into account that seizures develop on the third
day of perfusion, the main changes associated with the
epileptiform EEG activity were decreases in GABA and
Glu concentrations as well as significant increases in Gly
and Tau.
ESL and metabolite pharmacokinetics
Following oral administration of ESL (100 mg/kg), the
major metabolite in brain and plasma was eslicarbaze-
pine. Relatively low amounts of OXC were quantified in
brain and plasma. Only trace amounts of ESL were de-
tected in brain and no R-licarbazepine was detected.
Eslicarbazepine reached maximal concentrations (tmax)
between 0.5 to 4 h following administration and at 8 h
eslicarbazepine was in the elimination phase, reaching
undetectable levels 24 h following administration
(Figure 6). Previously, ESL was tested in mice at 20 mg/kg
[40]. In the present study we tested a dose of ESL 5 fold
that previously tested. The plasma and brain profile of
ESL and metabolites is similar in the two studies.
Discussion
The present study determined the effects of ESL on
epileptogenesis in the mouse latrunculin A model.
Moreover, brain amino acid concentrations in the hip-
pocampal microdialysates and ESL and metabolites in
brain and plasma pharmacokinetic data were obtained
for the pretreatment times and administration routes
used in the present study. As previously described for
mice [40,41], ESL was extensively converted to eslicar-
bazepine, as has been observed in humans [9-13]. In
contrast to mice and humans, rats extensively convert
ESL to oxcarbazepine [27]. ESL significantly prevented
latrunculin A-induced seizures and significantly pre-
vented chronic paroxysmal EEG activity in hippocam-
pal latrunculin A-perfused mice. These data indicate
that ESL inhibits seizure initiation and can protect
Figure 4 EEG recordings during wake (A) or sleep (B) in a mouse treated with ESL (100 mg/kg) prior to latrunculin A microperfusion.
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dose of ESL (100 mg/kg), which significantly increased
the seizure threshold in latrunculin A-perfused mice,
was similar to the dose that prevented the develop-
ment of seizures in the maximal electroshock test, andFigure 5 Extracellular aminoacid concentrations in control mice, after
represent mean values of 8 animals per group; vertical lines indicate
(# P < 0.05) or latrunculin A-treated mice (*P < 0.05) using the two-way ANOon partial-onset seizures in corneal and amygdala kind-
ling models [42].
These results suggest that ESL and eslicarbazepine
(the major metabolite after ESL administration) have the
potential to prevent latrunculin A-induced epileptogenesis.latrunculin A, and latrunculin A and ESL (100 mg/kg). Columns
SEM. Significantly different from corresponding values in control
VA followed by Holm-Sidak ? s multiple comparisons test.
Figure 6 Plasma and brain concentrations of eslicarbazepine
acetate (ESL), eslicarbazepine, (R)-licarbazepine and
oxcarbazepine (OXC) after oral administration ESL (100 mg/kg).
Columns represent mean values of 4 animals per group; vertical
lines indicate SEM.
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effect on partial onset seizures. However, disease-
modifying effects may also be involved. The mecha-
nisms of latrunculin A convulsant action are not com-
pletely understood, but the increase in the extracellular
concentrations of excitatory amino acids acting on
NMDA glutamate receptors, such as Glu, Asp and Gly,
seem to be involved in latrunculin A-induced changes
in seizure threshold [43,44]. It has been suggested that
changes in extracellular hippocampal Glu, Asp and
GABA levels are not involved in seizure onset, but may
play a role in seizure maintenance and/or spread in some
animal models of epilepsy [45]. In fact, high concentra-
tions of Glu and Gly are convulsant in rats treated with
intrahippocampal microperfusion of latrunculin A. This
effect can be reversed by NMDA antagonists [46], indi-
cating that increased Glu and Gly extracellular levels may
be involved in seizure initiation in latrunculin A-induced
seizures. The present study in mice shows that changes in
extracellular concentrations of brain amino acids during
latrunculin A hippocampal microperfusion are notidentical to that observed in rats [25]. This is particularly
relevant for Glu, where no increase in the extracellular
concentrations were observed in the mouse. Another in-
teresting difference between the rat and the mouse relates
to the marked decrease in the extracellular concentrations
of GABA in latrunculin A-treated mice, which did not
occur in the rat [25]. The differences between species in
what relates to changes in the extracellular concentrations
of Glu and GABA during latrunculin A hippocampal
microperfusion, for which no particular reason is appar-
ent, do not appear to play a relevant role with respect to
induction of seizures. However, it can be hypothesized
that the decrease in the extracellular concentrations of
GABA during latrunculin A hippocampal microperfusion
may play a role in seizure initiation, maintenance and
arrest [44,47,48]. On the other hand, the latrunculin A-
induced increase in the extracellular concentrations of
Asp and Gly appear to be common features in rats and
mice. The observation that ESL treatment prevented
latrunculin A-induced increases in the extracellular con-
centrations of Asp and Gly, without changes in GABA
levels, and the development of chronic seizures indicates
that the drug may not merely suppress seizure activity
but may also inhibit the generation of a constant hyperex-
citable epileptic network, resulting in decreases in the
extracellular levels of excitatory brain amino acids.
The delayed appearance of bilateral spike and wave
discharges, focal discharges or slow wave activity may re-
sult from changes in receptor signalling or changes in
synaptic connectivity of surviving cells. Multiple changes
occur in the days and weeks after convulsant application.
Long-term changes in receptor expression have been doc-
umented at both excitatory [49,50] and inhibitory synap-
ses [51]. Reactive changes have also been demonstrated in
the expression, phosphorylation and distribution of mem-
brane channels that regulate cellular excitability [52-54].
ESL is only hydrolysed to eslicarbazepine in humans
and mice [27], whereas oxcarbazepine serves as a pro-
drug of both 10-hydroxy metabolites, i.e. eslicarbazepine
and (R)-licarbazepine, which appear in the plasma and
urine in a 4:1 ratio [55,56]. In this context, it is of spe-
cific interest to compare the brain availability of both
enantiomers. Whereas eslicarbazepine was the major
metabolite in brain and plasma, (R)-licarbazepine repre-
sented less than 1% of the total amount of ESL metabo-
lites in brain. These data fit well with the finding that
eslicarbazepine was more potent in the MES test as
compared to the (R)-enantiomer [42]. Though (R)-licar-
bazepine is endowed with effects as an active voltage-
gated sodium channel (VGSC) blocker [18], this may not
suffice to guarantee efficacy of this entity as an anticon-
vulsant. Considerable differences in the pharmacody-
namic properties between eslicarbazepine and (R)-
licarbazepine have been observed. The affinity of (R)-
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inactive was found to be 4-fold that for eslicarbazepine
[18], which may favor a better efficacy of the later over
the former. Another remarkable difference between
eslicarbazepine and (R)-licarbazepine is concerned with
the potency of (R)-licarbazepine as a blocker of voltage-
gated potassium-channels, namely KV7.2 currents,
whereas eslicarbazepine is devoid of effect [57]. In fact,
activation of voltage-gated potassium-channels (KV7/
M) during the initial stages of an action potential dis-
charge suppresses later action potentials and inhibition
of channel activity strongly enhances repetitive firing
[58]. KV7.2 knock-out mice have a reduced electrocon-
vulsive threshold and increased sensitivity to convulsing
agents [59]. Finally, eslicarbazepine, but not (R)-licarba-
zepine, was effective in retarding kindling development
during bilateral corneal stimulation in mice [42]. This
potential for eslicarbazepine to elicit antiepileptogenic
effects, in contrast to (R)-Licarbazepine, may relate to
the ability of eslicarbazepine to effectively inhibit high
and low affinity Cav3.2 inward currents [17].
Numerous animal models of epileptogenesis have been
developed and used in research studies designed to in-
crease our understanding on the molecular abnormalities
underlying neuronal hyperexcitability and spontaneous
seizures [60]. The latrunculin A-induced acute and
chronic seizure model is an alternative model for studying
epileptogenesis, as seizures are not the consequence of a
previous sstatus epilepticus, but rather depend on the
long-term changes in neuronal excitability leading to the
onset of sporadic spontaneous seizures [25,26]. However,
to understand better the nature of the putative antiepilep-
togenic effect of ESL there is a need to evaluate whether
ESL administered after latrunculin A administration also
prevents the occurrence of chronic seizures. The effects of
ESL and its 10-hydroxy metabolite eslicarbazepine in this
model fit well with the outcome of the clinical experience
with ESL in epilepsy also considering data from the initial
proof‐of‐concept phase II study [1] as well as three sub-
sequent phase III studies in patients refractory to con-
ventional AED therapy [2-4]. Long-term safety and
maintenance of therapeutic effect was demonstrated in
one-year open-label extensions of these studies [6,7].
Conclusion
The data presented here demonstrate anticonvulsant ef-
fects of ESL on the development of latrunculin A-
induced seizures and paroxysmal EEG activity. ESL may
also exhibit disease-modifying effects beyond suppress-
ing just seizure activity, possibly by altering the develop-
ment of a hyperexcitable network, as evidenced by the
suppressed changes in glycine, taurine, glutamate and
aspartate concentrations associated with an antiepilepto-
genic effect.Methods
Animals
Adult NMRI (for MES test) or Swiss male mice, ob-
tained from Harlan-Interfauna or the animal facility of
the University of Santiago de Compostela, Barcelona,
Spain, with a body weight range of 35 ? 40 g were habitu-
ated for at least 5 days after delivery in macrolon cages
(25 ? 19 ? 13 cm; 10 animals per cage) on wood litter
with free access to food and water. Before starting the
experiments, mice were housed in individual cages
under controlled environmental conditions (ambient
temperature 21 ? 2?C, humidity 50-60%, 12:12 light/dark
cycle) with free access to food and water, except during
testing. All experiments were performed in laboratories
with controlled environmental conditions and at the
same time in the morning to avoid circadian variations.
All efforts were made to minimize animal suffering, and
chronic animal protocols were designed to reduce the
number of animals used. The experiments (GSP2010/
003) were authorised by the Ethics Committee of the
University of Santiago de Compostela (Spain) and
Dire??o Geral de Alimenta??o e Veterin?ria (Portugal)
and carried out according to procedures for handling
and caring of animals followed the Directive 2010/63/EU
of the European Parliament on the protection of animals
used for scientific purposes and the Spanish and Portu-
guese law on animal welfare. All efforts were made to
minimize animal suffering, and chronic animal protocols
were designed to reduce the number of animals used.
Maximal electroshock test
Male NMRI mice (n = 12-15 per group) were adminis-
tered MES (50 mA, rectangular current: 0.6 ms pulse
width, 0.4 s duration, 50 Hz) via corneal electrodes con-
nected to a constant current shock generator (Ugo Basile
7801) and the number of tonic convulsions recorded
[61]. Vehicle (0.2% hydroxypropylmethylcellulose in dis-
tilled water) and ESL were administered orally, at a vol-
ume of 10 ml/kg body weight, 60 minutes before the
test. Blood samples were taken from satellite groups of
mice 60 minutes after ESL administration.
EEG and microdialysis
Mice (n = 8 per group) were anaesthetized with pento-
barbital and placed in a stereotaxic instrument (D. Kopf,
Tujunga, CA, USA). Under aseptic conditions, 2 stain-
less steel microscrews serving as electrodes for EEG re-
cording were positioned in the skull above the frontal
and occipital areas of each hemisphere; the reference
electrode was anchored in the mid-line. The intracerebral
guide for the microdialysis probe was implanted vertically
into the ventral hippocampus. Stereotaxis coordinates
were 1.75 mm posterior, 2.3 mm lateral and 1.7 mm ven-
tral for the tip of the cannula relative to bregma and dural
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miniature plug (Cannon MD1-9SL1, ITT Cannon, Santa
Ana, USA) and fixed firmly to the skull with dental ce-
ment. The experiments were carried out on conscious,
freely moving mice 10 days after surgery. Bipolar cortical
EEGs were recorded using digital EEG system with con-
tinuous video monitoring. Videos were analyzed by two
observers blinded to the data.
We used a CMA/120 system for freely moving animals
with CMA/7 microdialysis probes. The probe was con-
nected via polyethylene tubing to a syringe selector
(CMA/111), and to 1 ml syringes mounted on a micro-
injection pump (CMA/100). Before starting each experi-
ment, the probe was perfused with ethanol and distilled
water. After checking the integrity of the probe under a
light microscope, vehicle solution was perfused for
10 min and in vitro recovery was tested routinely before
each experiment prior to placement in the mouse hippo-
campus via a chronically implanted intracerebral guide.
Treatments
The experiments were performed on freely-moving mice
10 days after surgery. After the fourth day mice were placed
daily for three hours in the experimental unit for habitu-
ation. Bipolar cortical EEGs were recorded using a digital
EEG system (MaxG, Zamora, Spain). In control experi-
ments, vehicle consisting of modified Ringer ? s solution
containing 1:18750 ethanol was perfused at a constant
flow rate of 1 μl/min for 7 h (from 09:00 am to 16:00 pm)
over three consecutive days (days 11 to 13 after surgery).
Latrunclin A-treated mice were perfused with latrunculin
A (4 μg/ml) following the same protocol; 7 h (from
09:00 am to 16:00 pm) over three consecutive days (days
11 to 13 after surgery). The dose of latrunculin A and the
place of probe implantation were selected based on the
previous experience in freely moving rats, in which latrun-
culin A hippocampal microperfusion resulted in acute epi-
leptic seizures as well as long term in neuronal excitability
leading to the onset of sporadic spontaneous seizures ac-
companied by changes in extracellular amino acid concen-
tration in the hippocampus [25,26]. Latrunculin A-treated
mice received orally via gavage vehicle or ESL (100 mg/
kg/day) suspended in water/carboxymethylcellulose 5?
10 min before starting each latrunculin A perfusion.
Following treatment, animals were continuously moni-
tored by video over one month, and the video records were
reviewed daily for indications of chronic spontaneous sei-
zures or any behavioral changes. Control EEG recordings
(8 h; from 09:00 am to 17:00 pm) were performed in all ani-
mals at least once per week over a minimum of one month.
Analysis of amino acids
Microdialysate samples were collected every 30 min over
6 hour period and sample analysis was performed by HPLCwith fluorimetric detection using the AccQ-Tag method
(Waters) for amino acids, as previously described by Liu
et al., [62] and Oreiro-Garc?a et al., [63]. In brief, the HPLC
system used was a Waters Alliance consisting of a 2695
separation model, a thermostat-controlled column oven, a
system interface module, and a 2475 scanning fluorescence
detector (all Waters components, Millipore, Milford, MA,
USA). A waters Empower 5.0.0. Chromatography Manager
was used to control system operation and results manage-
ment. Fluorescence detection monitored excitation at
250 nm and emission at 395 nm. In an analysis for aspar-
tate (Asp), glutamate (Glu), glycine (Gly), taurine (Tau),
10 μl of standards or sample was buffered to pH 8.8 with
10 μl of AccQ-Fluor borate buffer. In an analysis for
GABA, 15 μl of standards or sample was buffered to
pH 8.8 with 5 μl of AccQ-Fluor borate buffer. In both, the
derivatives were formed with 5 μl of AQC solution. The
reaction of AQC with all primary and secondary amines
was rapid and excess reagent was hydrolyzed within 1 min.
Separation of Asp, Glu, Gly and Tau, was carried out using
a 3.5 μm XBridge C18 column (100 mm ? 3.0 mm i.d.)
from Waters. Eluent A was aqueous acetate phosphate
buffer prepared by diluting AccQ-Tag eluent A concentrate
with water to a ratio of 1:10, eluent B was HPLC grade
acetonitrile and eluent C was water. The injection volume
was 5 μl and the separation was obtained at a flow rate of
0.7 ml/min at 30?C with the following gradient program:
initial 100% A; 0.5 min, 99% A; 21 min, 95% A; 21.5 min,
80% acetonitrile and 20% water; 28 min 100% A; all linear,
except the steps at 0.5 and 28 min which were a step func-
tion. For column regeneration, 6.5 min with 80% aceto-
nitrile and 20% water was sufficient to wash out the
column and before the next injection, 100% acetate buffer
for 10 min was needed to equilibrate the system. Separ-
ation of GABA was carried out using a 2.5 μm XBridge
C18 column (50 mm ? 2.1 mm i.d.) from Waters. Eluent A
was aqueous acetate phosphate buffer prepared by diluting
AccQ-Tag eluent A concentrate with water to a ratio of
1:10, eluent B was HPLC grade acetonitrile and eluent C
was water. The injection volume was 5 μl and the separ-
ation was obtained at a flow rate of 0.35 ml/min at 50?C
with the following gradient program: initial 99% A; 1 min,
99% A; 7 min, 97% A; 16 min, 89% A; 16.5 min, 80%
acetonitrile and 20% water; 25 min 100% A; all linear,
except the steps at 0.5 and 28 min which were a step func-
tion. For column regeneration, 8.5 min with 80% aceto-
nitrile and 20% water was sufficient to wash out the
column and before the next injection, 100% acetate buffer
for 10 min was needed to equilibrate the system. The sam-
ples were quantified with accuracy and precision over the
analytical range of 0.01 to 1.0 μmol/l for Asp and GABA,
0.1 to 10.0 μmol/l for glycine, glutamate and taurine. The
limit of quantification was 0.01 μmol/l for aspartate and
0.1 μmol/l for Glu, Gly and Tau.
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Brain and plasma concentrations of eslicarbazepine acetate,
eslicarbazepine and (R)-licarbazepine were determined
using a validated enantioselective LC-MS/MS assay, as
previously described [64]. In brief, Brain and plasma con-
centrations of eslicarbazepine acetate, eslicarbazepine and
(R)-licarbazepine were determined using a validated enan-
tioselective LC-MS/MS assay, as previously described [64].
Plasma samples (100 μL) were added with 400 μl of
internal standard (ISTD) working solution (2000 ng/ml of
10, 11-dihydrocarbamazepine in phosphate buffer pH 5.6)
and then processed by solid phase extraction. After thawing
and weighing, 0.1 M sodium phosphate buffer (pH 5.6) was
added to the brain samples to give a tissue concentration of
0.1 mg/ml. The samples were then homogenized using a
Heidolph DIAX 900 mixer and transferred to 10 ml plastic
centrifugation tubes. After centrifugation at 10,000 g for
30 min at 4?C, 0.5 ml of supernatants were added to 0.5 ml
ISTD working solution and then processed by solid phase
extraction. The samples were placed on an automatic liquid
handler (ASPEC-XL4, Gilson) for solid phase extraction.
Solid phase extraction cartridges (Oasis, HLB, 30 mg, 1 ml
Waters) were conditioned with 1 ml of acetonitrile and
then washed twice with 1 ml of water. Specimen (400 μl)
were loaded onto the cartridges and the cartridges washed
twice with 1 ml of water. After the second wash the car-
tridges were flushed with an air push of 10 ml at 6 ml/min.
The cartridges were eluted twice with 200 μl of methanol
with an air push of 2 ml at 6 ml/min. The eluted sample
was evaporated until dryness and resuspended into 200 μl
of hexane:2-propanol (90:10, v:v). The samples were
injected (20 μl) into a LC-MS/MS. The analysis of samples
extracts was performed using LC-MS/MS (Quattro
Ultima, Waters) with positive ion detection. Separation
was performed on a ChiralCel 0.46 cm ? 15 cm OD-H
column (Chiral technologies, Europe). The mobile phase
consisted of an isocratic mixture of hexano:ethanol
(80:20, v:v; flow rate of 1 ml/min), and Ethanol with
5 mM ammonium acetate (added post-column using a
flow rate of 0.15 ml/min). A volume of 20 μL was injected
and the column temperature kept at 50?C for the run
time of 7 min. Electrospray ionisation was used for all
mass spectrometer methods with a cone voltage of 40 V
and capillary current of 3.8 kV. The multiple reaction
monitoring pair was m/z 239.1→ 194, collision 40 eV for
ISTD; 253.1→ 208, collision 25 eV for oxcarbazepine;
255.1→ 194, 237, collision 30 eV for eslicarbazepine and
(R)-licarbazepine; 297.1→ 194, 237, collision 30 eV for
eslicarbazepine acetate. The autosampler cooler was
maintained at 10?C. The samples were quantified with
accuracy and precision over the analytical range of 0.2 to
8.0 nmol/ml for plasma and 2.0 nmol/g to 80 nmol/g for
brain. The limit of quantification was 0.2 nmol/ml and






10,11-dihydrocarbamazepine (used as internal standard),
and oxcarbazepine, were all synthesized in the Labo-
ratory of Chemistry, BIAL ? Portela & C?, S.A., with
purities >99.5%. Latrunculin A was obtained from Mo-
lecular Probes (Eugene, Oregon, USA).
Statistical analysis
Results are presented as mean ? SEM. EEG records were
analysed using the Medlog 9200 software, version 7.2. Spike
and wave discharges duration, seizure duration, and num-
ber of seizures were evaluated. Statistical significance of the
difference in number of seizures, seizure duration, and
seizure onset times was determined by two-way ANOVA
followed by Holm-Sidak? s multiple comparisons test.
Significant differences in amino acid levels were determined
by two-way ANOVA for repeated measures followed by
Holm-Sidak? s multiple comparisons test. P-values less than
0.05 were regarded as statistically significant.
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